Project APOLLO
Anti-fibrotic phototherapy for scleroderma
ResearchActive
Key Facts
About LightOx
LightOx, founded in 2016 and based in Newcastle, UK, is advancing a platform of light-activated small-molecule drugs. Its lead candidate, LXD191, is a topical gel for early-stage oral cancer, with plans to enter a Phase I/IIa clinical trial in 2025. The company has a strong IP position with five global patents, has secured strategic partnerships, and is exploring platform expansion into anti-fibrotic and non-oncology applications.
View full company profile